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CX3C chemokine receptor 1 deficiency 
modulates microglia morphology but does 
not affect lesion size and short-term deficits 
after experimental stroke
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Abstract 
Background: The fractalkine/CX3C chemokine receptor 1 (CX3CR1) pathway has been identified to play an essential 
role in the chemotaxis of microglia, leukocyte trafficking and microglia/macrophage recruitment. It has also been 
shown to be important in the regulation of the inflammatory response in the early phase after experimental stroke. 
The present study was performed to investigate if CX3CR1 deficiency affects microglia during the first 14 days with 
consequences for tissue damage after experimental stroke.
Results: CX3CR1 deficiency significantly increased the number of intersections of GFP positive microglia in the 
proximal peri-infarct area at 2, 7 and 14 days following tMCAO compared to heterozygous and wildtype littermates. 
In addition, the length of microglial branches increased until day 7 in CX3CR1 knockout mice while the presence of 
a functional CX3CR1 allele resulted in a gradual reduction of their length following tMCAO. After stroke, wildtype, 
heterozygous and CX3CR1 deficient mice did not show differences in the composite neuroscore and assessment of 
infarct volumes from CX3CR1 wildtype, heterozygous and deficient mice revealed no differences between the geno-
types 7 and 14 days after stroke.
Conclusion: Results demonstrate that CX3CR1 deficiency affects the morphology of GFP positive microglia located 
in the proximal peri-infarct region during the first 14 days after tMCAO. Our data also indicate that CX3CR1 deficiency 
does not affect definite infarct volumes. Modulation of the CX3CR1 pathway may have implication for microglia func-
tion contributing to mechanisms of tissue reorganization in the post-ischemic brain.
© The Author(s) 2017. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
For development of new therapeutics in stroke, it is 
important to understand mechanisms of tissue reor-
ganisation in the brain after ischemia. Based on recent 
studies it is clear that parallel and partially opposite pro-
cesses contribute to restoration of brain function. The 
interaction of multiple mechanisms including neuronal 
plasticity, astrogliosis, cell- and angiogenesis and inflam-
mation are important for the final outcome after stroke.
During the recovery process, the release of pro-
inflammatory molecules can initiate and perpetuate the 
local inflammatory response in the postischemic brain 
[1]. Examples of these molecules are free DNA, mem-
brane compounds, oxidized lipids and free radicals, 
and they can be referred to as danger associated mole-
cules (DAMPs). DAMPs can bind to receptors on brain 
resident microglia and astrocytes [2]. Cytokine and 
chemokine release increases, as does the expression of 
adhesion molecules on brain resident cells and in par-
ticular endothelial cells. Circulating immune cells bind to 
these molecules and migrate into the ischemic territory. 
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These cells also release neurotoxic cytokines, chemokines 
and free radicals, which may exacerbate the inflamma-
tory process [3, 4]. On the other hand, inflammatory 
processes contribute to tissue repair. Macrophages clear 
up the necrotic debris, and immune cells as well as pro-
inflammatory cytokines are involved in facilitating neu-
ronal plasticity [5].
Accumulation of immune cells is a well-regulated pro-
cess and even weeks after stroke, immune cells can be 
detected in the ischemic territory [6]. Microglial cells are 
resident macrophages of the brain, and play a major role 
in post-injury inflammation. In the healthy brain they 
survey the environment, and the cells are characterized 
by a ramified appearance [4, 7]. In different brain pathol-
ogies, however, microglial cells transform associated with 
the expression of different cell surface receptors, produc-
tion of immune mediators, and the capacity to phagocyt-
ise. In this state, they are indistinguishable from recruited 
peripheral macrophages. Previous studies have demon-
strated that after stroke microglia adapt a pro-inflamma-
tory state and contribute to post-ischemic inflammation 
[4, 8, 9].
Fractalkine (CX3CL1) is a chemokine that, in the brain, 
is expressed mainly by neurons, although there are some 
studies indicating an expression by glial cells as well [10–
14]. Fractalkine exists in a membrane-bound form and, 
after proteolytic cleavage by ADAM10 or ADAM17, in a 
soluble form [15, 16]. Membranous fractalkine is involved 
in mechanisms of cell adhesion, its soluble form can act 
as chemoattractant [11]. The sole receptor for fractalkine 
is CX3C chemokine receptor 1 (CX3CR1) expressed on 
different immune cell populations [12, 17–19]. Within 
the first hours after ischemic injury, fractalkine expres-
sion is increased in necrotic neurons in the infarct core 
[18]. During the first week after stroke, there is also a 
delayed upregulation of fractalkine in cells of the peri-
infarct area [20]. CX3CR1 positive cells can be detected 
in the ischemic tissue after 24  h, and the number of 
CX3CR1 positive microglia is strongly up-regulated dur-
ing the first weeks after permanent focal ischemia [20].
The present investigation was conducted to study the 
effect of CX3CR1 deficiency on definitive tissue damage 
in the postischemic brain after tMCAO. Based on pre-
vious studies, we hypothesized that CX3CR1 deficiency 
may contribute to the morpholgy of microglia in the 
proximal peri-infarct area during the first 2  weeks with 
possible consequences for their function and contribu-
tion to recovery of lost neurological function after stroke.
Methods
Animals
For the present study transgenic male C57/B6 mice 
that carried green fluorescent protein (GFP) under 
control of the CX3CR1-promoter (CX3CR1GFP/GFP 
and CX3CR1GFP/+) and CX3CR1+/+ wildtype lit-
termates were used (age between 10 and 16  weeks). 
While CX3CR1GFP/GFP animals do not express a func-
tional receptor [referred to as knockout (ko) mice], 
CX3CR1GFP/+ mice [referred to as heterozygous 
(hz) mice] express GFP but still have one allele for 
a functional CX3CR1 receptor. Mice were bred as 
CX3CR1GFP/+ mice and offspring littermates have been 
used for experiments. As previously described [18] no 
phenotypic differences have been observed between the 
genotypes, body weights of wildtype (CX3CR1+/+) and 
deficient (CX3CR1GFP/GFP) mice did not differ before 
surgery (wt: 24.5 ± 3.4 g; ko: 25.9 ± 3.3 g) and on day 7 
after tMCAO (wt: 21.4 ± 4.1 g; ko: 21.9 ± 2.6 g). All ani-
mal procedures included in this study were approved by 
the Malmö/Lund ethical committee. Experiments were 
carried out according the ARRIVE criteria to perform 
animal experiments and were blinded to the experimen-
tators performing the surgeries.
Transient occlusion of the middle cerebral artery
Mice were anesthetized by inhalation of initially 1.5% 
isofluorane in O2:N2O (30:70) and sustained at 1.0% 
to 1.2% throughout the occlusion period (IsobaVet, 
Schering-Plough Animal Health, Milton Keynes, UK). 
Body temperature was kept at 37 °C. Regional cerebral 
blood flow (rCBF) was monitored through an optical 
fibre probe (Probe 318-I, Perimed, Järfälla, Sweden) 
fixed to the skull at 1 mm posterior and 3.5 mm lateral 
to Bregma and connected to a laser Doppler flow meter 
(Periflux System 5000, Perimed). A customized silicon 
rubber-coated monofilament (Doccol Corporation) 
size 6–0, diameter 0.09–0.11 mm, length 20 mm; diam-
eter with coating 0.25 ±  0.02  mm to 0.27 ±  0.02  mm 
(adapted to the age and weight of the animal) was 
inserted into the common carotid artery and advanced 
into the internal carotid artery until the origin of the 
middle cerebral artery (MCA), given by a sudden drop 
in rCBF. After 45 min, the filament was withdrawn and 
reperfusion was observed. The animals were placed in 
a heating box at 37 °C overnight, to avoid post-surgical 
hypothermia. Physiological parameters body weight 
and body temperature have been monitored through-
out the first week of the study. In order to analyze the 
inflammatory response after tMCAO, CX3CR1 het-
erozygous and knockout mice have been sacrificed on 
day 2, 7 or 14 after tMCAO. In total 67 mice (wt: 23; 
hz: 18; ko: 26) were operated. Out of those 26 mice (wt: 
9; hz: 5; ko: 12) died during the first 4 days of the study 
and were not included in the analysis. Numbers of ani-
mals included in analyses are indicated in respective 
figure legends.
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Behavioral assessment
Neurological deficits were assessed by a composite neu-
roscore containing the following tests: (1) animal rotation 
(0–5 points; 0—barely able to move but if so, moving cir-
cularly, 1—big impairment, totally rotating over the body 
axis or with parallel dislocation, 2—big impairment, able 
to walk while circumscribing small circles, 3—rotated 
in medium to big sized circles, 4—rotates in big circles 
but is able to walk straight, 5—normal function); (2) paw 
placement test (0–5 points; 0—paw totally immobilized, 
hanging down, no movement, 1—paw hanging, but lit-
tle movement back and forth (horizontal plane), 2—paw 
hanging, horizontal and vertical movement below table’s 
level, 3—paw hanging horizontal and vertical movement 
up to table’s surface level, 4—paw hanging, mobile in all 
directions, reaching the table’s surface, 5—normal, paw is 
immediately taken up to the table’s surface); (3) forelimb 
flexion on suspension test (0–4 points; 0—impaired paw 
is not moving and tightly held to the trunk, 1—impaired 
paw mostly held to the trunk, slightly movable, 2—
impaired paw moves up and down, asymmetry to other 
paw, 3—slight asymmetry between the paws, both paws 
well movable, 4—normal, symmetric); (4) hind limb flex-
ion response (0–4 points; 0—impaired paw is not mov-
ing and tightly held to the trunk, 1—impaired paw mostly 
held to the trunk, slightly movable, 2—impaired paw 
moves up and down, asymmetry to other paw, 3—slight 
asymmetry between the paws, both paws well movable, 
4—normal, symmetric) and (5) lateral pulse test (0–4 
points; 0—severely impaired and asymmetrical, 1—
impaired, distinct asymmetry, 2—partially impaired, visi-
ble asymmetry in response to pulse, 3—slightly impaired, 
almost no asymmetry, 4—normal). Animals have been 
tested on day 1 after the surgery and the maximum score 
to achieve was 22 points [20].
Immunohistochemistry
Brain sections (thickness 30  µm) from 4% paraform-
aldehyde-perfused animals were rinsed in phosphate 
buffered saline (PBS). Endogenous peroxidase activ-
ity was quenched by washing the sections in a solution 
of PBS with 3% H2O2 and 10% methanol for 15  min. 
After subsequent rinsing in PBS, blocking was achieved 
by incubation in a solution containing 5% normal don-
key serum (NDS) in 0.25% Triton X-100 in PBS (Tx/
PBS) for 1 h. Thereafter, sections were incubated with a 
mouse anti neuronal nuclei (NeuN) antibody (diluted 
at 1:1000, Merck Millipore, Billerica, MA, USA) at 4  °C 
in 5% NDS in Tx/PBS overnight. The next day, sections 
were rinsed in 1% NDS in Tx/PBS followed by incuba-
tion with respective biotinylated secondary antibodies 
in 2% NDS in Tx/PBS at room temperature for 90  min. 
Sections were washed with Tx/PBS and incubated with 
avidin–biotin-complex (ABC) (Vector Laboratories, CA, 
USA) for 1 h. Following this incubation, the sections were 
rinsed in PBS. The ABC reaction was visualized using 
NiDAB (DAB (Dabsafe, Saveen Werner AB, Sweden)) 
with the addition of NiCl2 and a mixture of 3% H2O2 in 
H2O. Thereafter, sections were rinsed in PBS, mounted 
on glass slides, dried overnight, dehydrated, treated with 
xylene and then cover-slipped with Pertex. (Histolab AB, 
Sweden).
Immunofluorescence
Brain sections (thickness 30 µm) from 4% paraformalde-
hyde-perfused animals were washed in PBS (3 × 10 min), 
blocking was achieved by 5% normal donkey serum in 
Tx/PBS for 60  min. The sections were then incubated 
with primary antibody (neuronal nuclei (NeuN), Merck 
Millipore, Europe; diluted at 1:1000 (ms antibody) or 
1:5000 (rb antibody)) in Tx/PBS in 5% NDS at 4 °C over-
night. The next day, the sections were rinsed with 1% 
NDS in Tx/PBS thrice for 10 min. All following steps have 
been performed in darkness in order to preserve the fluo-
rophore conjugated to the secondary antibody. Sections 
were incubated with the secondary antibodies conju-
gated either with biotin or Cy3 (each diluted at 1:400) in 
2% NDS in Tx/PBS for 90 min at room temperature and 
rinsed in PBS thrice for 10 min. Thereafter, sections incu-
bated with biotinylated secondary antibody have been 
incubated with AF488 conjugated streptavidin (1:400) 
for 60  min at room temperature. Finally, the sections 
were rinsed in PBS thrice for 10 min and mounted on 
supercharged glass slides (Menzel, Braunschweig, Ger-
many), allowed to dry, cover-slipped using PVA-DABCO 
(Saveen-Werner, Malmö, Sweden) and analysed using 
LSM 510 confocal microscopy (Zeiss Jena, Germany).
Infarct size measurements
Brains from perfusion fixed animals were cut into coro-
nal sections with a thickness of 30  µm and stained for 
neuronal nuclei (NeuN) [20]. The noninjured portion of 
the ipsilateral and contralateral hemisphere were encir-
cled and the indirect infarct volume was calculated by 
integration of areas from serial sections of each brain as 
described previously [20].
Sholl analysis
Sholl analysis determines the number of intersections 
of a cell with a subset of circles, with increasing diame-
ters starting from the centre of the cell (Fig. 1) [21]. This 
gives an indication of the degree of ramification of a cell. 
Z-stacked micrographs from coronal brain sections of 
CX3CR1+/+, CX3CR1GFP/+ and CX3CR1GFP/GFP mice (3 
sections per animals from the following levels related to 
bregma: 1.2–1.0; 0; −1.0 to −1.2) stained for NeuN were 
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acquired using a Zeiss LSM510 laser scanning confocal 
microscope and merged into a single plane image using 
the LSM Image Browser software. Based on the NeuN 
staining the peri-infarct area was defined as follows: the 
NeuN staining was used to delineate the infarct border 
with a line (line I). From this line, a 200 µm long line was 
drawn at 90 degrees (line II). Parallel to line I, a line (line 
III) was drawn at the endpoint of line II to mark the distal 
border of the peri-infarct area. Using these coordinates, 
the rectangular area was used for analysis of Iba-1+ or 
GFP+ cells (Fig. 1a). Per picture, randomly 50 cells were 
selected in the peri-infarct area, using a circle with a cir-
cumference of 140  µm (140/π in diameter). The follow-
ing selection criteria for analysis were defined: (1) a cell 
needed to fit in the circle completely; (2) a cell needed to 
have a visible soma and (3) a cell should not overlap with 
other cells. The extracted cells were saved in separate 
TIFF files. Using ImageJ pictures were converted to 8-bit 
files with a set threshold [22]. The center of a cell was 
defined manually, and Sholl analysis was performed with 
a starting radius of 3 pixels and steps of 1 pixel. Starting 
with a circle with a diameter of 3 pixels and expanding 
the circles with 1 pixel every time, intersections per cir-
cle were counted using the ImageJ Sholl analysis plugin. 
Results from each cell per conditions were integrated and 
analyzed using Microsoft Excel. Analysis has been per-
formed blinded to the examiner.
Statistical analysis
Statistical analysis was performed using Excel and IBM-
SPSS (Version 22, IBM, Stockholm, Sweden). Sholl analy-
sis data are presented as medians with the 25th and 75th 
percentiles. Comparison between groups was performed 
using the Student’s t test for GFP positive cells and 
Kruskal–Wallis analysis for Iba-1 positive cells. Infarct 
volumes are presented as mean  ±  standard deviation 
(SD). Statistical analysis has been performed by one-way 
analysis of variance. No statistical difference has been 
reached at 7 days (p = 0.3049) and 14 days (p = 0.6128), 
posthoc corrections were not performed. Neuroscore 
data are presented as medians with the 25th and 75th 
percentiles and whiskers. Statistical analysis have been 
performed by the Kruskal–Wallis test (p = 0.8196).
Results
Effect of CX3CR1 deficiency on the morphology 
of microglia after stroke
Previous studies provided data showed that CX3CR1 defi-
ciency affects the morphology of immune cells in the 
ischemic territory during the first 24  h after stroke [23]. 
Fig. 1 Definition of the region of interest for Sholl analysis. a Regions of interest for cell analysis and different morphologies of GFP+ cells.  
b1 amoeboid cell, b2 intermediate ramified cell, b3 ramified cell. c Superimposed micrograph showing NeuN (Cy3, red) and GFP+ cells in the 
ischemic hemisphere, the infarct core and adjacent peri-infarct area, scale bar 200 µm
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We hypothesized that microglia morphology indicative 
for their activation status is affected by the presence of 
CX3CR1 beyond the time window of neuroprotection 
after stroke. An established Sholl analysis protocol has 
been applied to study the morphology of GFP+ cells in 
the peri-infarct area of CX3CR1GFP/+ (heterozygous) and 
CX3CR1GFP/GFP (knockout) mice at 48 h, 7 and 14 days after 
transient occlusion of the middle cerebral artery (tMCAO) 
(Fig.  1). Coronal sections were stained for the neuronal 
marker NeuN in order to exactly delineate the infarct 
border. As shown in Fig. 2, GFP+ cells from heterozygous 
mice displayed less intersections compared to GFP+ cells 
in knockout mice at all three time points. In addition, the 
number of intersections decreased over time in heterozy-
gous mice. In contrast, ramification of GFP+ microglia in 
knockout mice further increased until day 7 after tMCAO 
and only declined 14  days following tMCAO to levels 
found on day 2. To assess the data for statistical analysis, 
intersections were grouped depending on distance from 
the center of a cell (5–10, 10–15, 15–20 and 20–25 µm). As 
shown in Fig. 2b, a significant higher number of intersce-
tions was observed in CX3CR1 deficient mice compared to 
heterozygous littermates at all time points and in all groups 
after tMCAO. Likewise, Sholl analysis from Iba-1 positive 
cells showed a significant higher number of intersections in 
CX3CR1GFP/+ and CX3CR1GFP/GFP mice at 48 h (Fig. 3). In 
contrast, to the analysis based on GFP positive cells analy-
sis of intersections showed no differences in intersections 
between CX3CR1GFP/+ and CX3CR1GFP/GFP mice at 48  h 
and 7 days following PT. At 14 days after PT a reduction 
of interscections was observed in CX3CR1GFP/+ mice com-
pared to knockout littermates. The number was similar 
to the number found in wildtype mice, however, did not 
reach statistical significance. Results are supported by mor-
phology of Iba-1 positive microglia cells in the proximal 
peri-infarct area (Fig. 4). While microglia cells in wildtype 
animals displayed a more stellate morphology, cells found 
in knockout mice appeared with bigger soma and thicker 
branches (Fig.  4a, b). On day 14, morphology appeared 
more equalized, however, with a lower number of intersec-
tions in wildtype microglia (Fig. 4c, d). From this analysis 
we conclude that CX3CR1 deficiency significantly affects 
ramification of microglia cells in the proximal peri-infarct 
area after tMCAO. The level of ramification might be 
indicative for a different status of cell activation in animals 
expressing a functional CX3CR1 receptor.
Fig. 2 Sholl analysis after transient occlusion of the middle cerebral artery. a Distribution of intersections in heterozygous and knockout mice at 
48 h, 7 and 14 days after tMCAO. Data are presented as medians with the 25th and 75th percentiles. In total 3 sections per animal were analyzed of 
animals: hz 48 h = 2, hz 7 days = 2, 14 days hz = 3, ko 48 h = 3, ko 7 days = 3, ko 14 days = 3. b Number of crossing in the indicated intervals in 
heterozygous and knockout mice at 48 h, 7 and 14 days after tMCAO. Data are presented as medians with the 25th and 75th percentile. Statistical 
analysis has been performed by using the Student’s t test for individual interval groups: *p < 0.05, ***p < 0.001
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Impact of CX3CR1 deficiency on infarct volume 
and functional outcome after tMCAO
Seven and 14  days after tMCAO, mice were perfu-
sion fixed and series of coronal sections with defined 
distances were stained for the neuron specific marker 
NeuN. Based on NeuN immunoreactivity the noninjured 
portion of the ischemic hemisphere and the contralat-
eral hemisphere were encircled and infarct volumes 
were calculated as described previously (Fig. 5a) [24]. As 
shown in Fig. 5b, infarct volumes did not differ between 
the wildtype (33.23  ±  6.5  mm3, n  =  5), heterozygous 
(22.5  ±  7.5  mm3, n  =  5) and CX3CR1 deficient mice 
(29.84 ± 7.5 mm3, n = 5) on day 7 and day 14 (wt: n = 6, 
25.32 ± 8.9 mm3; hz: n = 3, 26.9 ± 8.5 mm3; ko: n = 6, 
27.78 ±  9.2  mm3). Likewise, no differences in the neu-
rological tests have been obtained in wildtype (n = 12) 
mice compared with heterozygous (n = 11) and CX3CR1 
deficient mice (n  =  14) after tMCAO (Fig.  5c). From 
these experiments we conclude that CX3CR1 deficiency 
did not affect the loss immediate neurological function 
and also has no effect on the definitive lesion size after 
transient occlusion of the middle cerebral artery for 
45 min (Fig. 5).
Discussion
The present study was conducted to characterize the 
inflammatory response and in particular the relevance of 
CX3CR1 on microglia morpholgy and lesion size during 
the first 14  days after transient occlusion of the middle 
cerebral artery. We found that CX3CR1 deficiency sig-
nificantly altered the microglial response in the proxi-
mal peri-infarct area. We also provide the evidence that 
CX3CR1 knockout per se has no effect on lesion size and 
early functional outcome after tMCAO. We will discuss 
the relevance of CX3CR1 activation for immune cell acti-
vation after stroke. Moreover, we will elaborate on the 
consequences of CX3CR1 knockout on different results 
obtained in previous studies in regard to functional out-
come and lesion size after experimental stroke.
Relevance of CX3CR1 for immune cell activation 
after stroke
It has been shown that activation of the CX3CR1 recep-
tor is involved in microglia/leukocyte trafficking [10, 16, 
19, 25, 26] and phagocytosis [23, 27]. These processes are 
associated with changes in cell morphology. In the present 
study Sholl analysis has been performed to test if changes 
Fig. 3 Sholl analysis of Iba-1 positive microglia in the proximal peri-infarct area. a Distribution of intersections in wildtype, heterozygous and 
knockout mice at 48 h, 7 and 14 days after tMCAO. Data are presented as medians with the 25th and 75th percentiles. In total 3 sections per animal 
were analyzed of animals: wt 48 h = 3, wt 7 days = 4, 14 days wt = 4, hz 48 h = 2, hz 7 days = 3, 14 days hz = 3, ko 48 h = 3, ko 7 days = 3, ko 
14 days = 6. b Number of crossing in the indicated intervals in heterozygous and knockout mice at 48 h, 7 and 14 days after tMCAO. Data are pre-
sented as medians with the 25th and 75th percentile. Statistical analysis has been performed by Kruskal–Wallis: *p < 0.05 versus wt, #p < 0.05 versus 
hz
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in ramifications in GFP+ cells depend on a functional 
CX3CR1 receptor in the peri-infarct area after tMCAO. 
We observed a significant higher number of ramifications 
in CX3CR1 deficient mice compared to heterozygous lit-
termates at 2, 7, and 14 days after tMCAO. Similar results 
have been obtained 24 h after tMCAO [23]. In addition, we 
performed Sholl analysis based on Iba-1 immunoreactivity. 
Also here, a significant higher number of intersections was 
observed in CX3CR1 deficient mice. These results might be 
indicative for a function of the CX3CR1 in regard to mor-
phological changes of brain resident microglia in the pos-
tischemic hemisphere. Throughout the observation period 
of 14 days after tMCAO, a continuous reduction of inter-
sections and a reduction in length of microglial branches 
were found in mice with a functional CX3CR1 allele. In 
contrast, an increase of intersections (GFP positive cells) 
or higher number of intersections at all time points (Iba-1 
positive cells) were observed in CX3CR1 deficient mice 
during the first week after tMCAO with the biggest dif-
ference between the genotypes during the first week after 
tMCAO. Described morphological changes between the 
genotypes might be linked to changes of microglia func-
tion, such as phagocytosis, as shown previously [20, 23, 
27]. Our results may also support earlier studies describing 
reduced phagocytosis in cultivated wildtype microglia cell 
treated with fractalkine [27]. Differences in microglia mor-
phology between the genotypes might also be explained 
by their susceptibility to the endogenous CX3CR1 ligand 
fractalkine. We have shown that AMD3100, an irrevers-
ible antagonist on the CXCR4 and partial agonist on the 
CXCR7, reduced the level of fractalkine in CX3CR1 het-
erozygous mice. Treatment is associated with a reduced 
number of microglia and a deduction of their soma size 
in the proximal peri-infarct area [20]. Together, results 
suggest that the dynamics of microglia morphology and 
activation are a very fine tuned processes. Already slightly 
elevated levels of fractalkine found in wildtype and het-
erozygous mice but also the lack of CX3CR1 and down-
stream signaling cascades may have consequences for 
microglia function such as the release of pro-inflammatory 
molecules [20].
The role of the fractalkine/CX3CR1 pathway for functional 
outcome and tissue damage after stroke
To reiterate, initial studies have demonstrated that the 
fractalkine/CX3CR1 pathway is instrumental in chemo-
taxis of microglia [12, 25], leukocyte trafficking and 
microglia/macrophage recruitment [16]. In in vitro mod-
els fractalkine showed neuroprotective properties [28] 
by activation of neuronal cell survival pathways [29], 
and fractalkine also led to increased survival of micro-
glia [30]. In addition, CX3CR1 deficient mice subjected 
to transient occlusion of the middle cerebral artery 
(tMCAO) showed smaller infarct volumes compared 
Fig. 4 Microglia morphology after transient occlusion of the middle cerebral artery. Immunofluorescence analysis of Iba-1 positive cells (AF488, 
green) in a wildtype mouse (a, higher magnification in a1) and CX3CR1 deficient mouse (b, higher magnification in b1) on day 2 and in a wildtype 
mouse (c, higher magnification in c1) and CX3CR1 deficient mouse (d, higher magnification in d1) on day 14 (c, higher magnification in c1) follow-
ing PT. Sections were costained with NeuN (Cy3, red). Scale bars a–d 50 µm; a1–d1 10 µm
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to heterozygous and wildtype littermates analyzed 72  h 
after tMCAO. CX3CR1 deficient animals also showed 
reduced levels of pro-inflammatory cytokines. Reduced 
levels of pro-inflammatory cytokines and reduced num-
bers of accumulating immune cells, however, might 
have been the result of smaller infarcts [31, 32]. Findings 
have been confirmed in a model of permanent MCAO 
(pMCAO) [27]. Moreover, administration of fractalkine 
to wildtype mice also resulted in smaller infarcts suggest-
ing neuroprotective actions of the fractalkine/CX3CR1 
pathway. In contrast, administration of fractalkine to 
fractalkine deficient mice resulted in bigger lesions. Sum-
marizing both studies, administration of fractalkine but 
also CX3CR1 deficiency seem to be beneficial after exper-
imental stroke and models of neurodegeneration [19]. 
We, therefore, aimed at studying the effect of CX3CR1 
deficiency on acute functional deficits and definite 
lesion size. As described above, no differences have been 
observed between CX3CR1 deficient mice and wildtype 
littermates. Results are based on a sufficient number of 
animals included in the studies, physiological param-
eters have been controlled tightly and mortality was not 
different between the study groups. Infarct size measure-
ments have been performed based on NeuN immuno-
reactivity, and respective areas (see “Methods” section) 
have been encircled with the aid of microscopic control. 
In our approach we applied a commonly used mouse anti 
NeuN antibody, hence it needs to be considered that sub-
sequent application of secondary anti mouse antibodies 
resulted in crossreactivity with extravasated IgG’s in the 
ischemic core. This can be eliminated by the use of mouse 
anti NeuN antibodies directly conjugated with biotin 
or anti NeuN antibodies from other species. However, 
detection of IgG extravasation can facilitate distinction 
between intact and ischemic brain tissue. Shrinkage of 
tissue has been eliminated by indirect infarct size meas-
urements as described previously [24]. The approach to 
stain postischemic brains (TTC versus NeuN immuno-
histochemistry) as well as different time points of infarct 
size measurements may explain the differences between 
the studies. Although different methods are available 
to evaluate the size of brain lesions after experimental 
stroke [33] our data suggest that results from low resolu-
tion methods such as TTC or MRI should be verified by 
Fig. 5 Functional outcome and lesion volumes after tMCAO. a Representative coronal sections from a wildtype (wt) and a CX3CR1 deficient (ko) 
mouse at day 7 following tMCAO. The encircled brain regions (contralateral hemisphere and non-injured part of the ischemic hemisphere) were 
used for lesion volume calculations. b Infarct volumes on day 7 and day 14 in wildtype (wt), heterozygous (hz) and CX3CR1 deficient mice (ko). Data 
are presented as mean ± SD. One-way analysis of variance. No statistical difference has been obtained at 7 days (p = 0.30) and 14 days (p = 0.61), 
respectively. c Composite neuroscore obtained on day 1 after tMCAO from wildtype (wt; n = 12), heterozygous (hz; n = 11) and CX3CR1 deficient 
mice (ko; n = 14). Scores are presented as medians with the 1st and 3rd quartile and whiskers. No statistical difference was found between the 
experimental groups (Kruskal–Wallis, p = 0.82)
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immunohistochemistry. In addition, analysis of ischemic 
lesions should be performed at a time point when the 
infarct has been subsided and edema has been resolved. 
Since differences are apparent between experimental 
stroke models and investigators, analysis should not be 
performed before day 7 after stroke. From our studies we 
conclude that CX3CR1 deficiency has no impact on acute 
functional outcome and did not affect lesion size after 
tMCAO.
Conclusion
We show that CX3CR1 significantly contributes to 
changes in microglia morphology in the proximal peri-
infarct area following tMCAO. Morphological altera-
tions suggest a shift in microglia functionality integrated 
in the inflammatory response after stroke. We also dem-
onstrate that CX3CR1 deficiency has no beneficial effect 
on lesion size neither it affects early functional outcome 
after stroke. This, in first line, can be explained by similar 
lesion sizes in mice of the different genetic backgrounds. 
Changes in the number of branches might have conse-
quences in the interaction of microglia with other glial 
cell populations and neurons. Therefore, modulation of 
microglia in morphology and function, e.g. by pharma-
cological means, might be a therapeutic strategy to opti-
mize tissue reorganization in the post-ischemic brain.
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